Fadrozole

• CAT Number: I011409
• CAS Number: 102676-47-1
• Molecular Formula: C14H13N3
• Molecular Weight: 223.27
• Purity: ≥95%
• Synonyms: 4-{5H,6H,7H,8H-imidazo[1,5-a]pyridin-5-yl}benzonitrile
• Target: Cytochrome P450
• Storage: RT

Fadrozole (CAT: I011409) is a nonsteroidal aromatase inhibitor that is primarily used in the treatment of estrogen-dependent breast cancer. Aromatase is an enzyme that converts androgens into estrogens, and inhibiting this enzyme can help reduce estrogen levels in the body. By blocking aromatase, fadrozole reduces estrogen production and subsequently inhibits the growth of hormone receptor-positive breast cancer cells. It is typically administered orally and has shown efficacy in both early-stage and advanced breast cancer cases.

Reference

1: Browne LJ, Gude C, Rodriguez H, Steele RE, Bhatnager A. Fadrozole
hydrochloride: a potent, selective, nonsteroidal inhibitor of aromatase for the
treatment of estrogen-dependent disease. J Med Chem. 1991 Feb;34(2):725-36.
PubMed PMID: 1825337.
2: Raats JI, Falkson G, Falkson HC. A study of fadrozole, a new aromatase
inhibitor, in postmenopausal women with advanced metastatic breast cancer. J Clin
Oncol. 1992 Jan;10(1):111-6. PubMed PMID: 1530798.
3: Falkson G, Raats JI, Falkson HC. Fadrozole hydrochloride, a new nontoxic
aromatase inhibitor for the treatment of patients with metastatic breast cancer.
J Steroid Biochem Mol Biol. 1992 Sep;43(1-3):161-5. PubMed PMID: 1388048.